Dermatologic Therapy最新文献

{"title":"The Role of Oxygen Tension in Modulating Wound Healing Phases","authors":"Arezo Azari,&nbsp;Simzar Hosseinzadeh,&nbsp;Faraz Sigaroodi,&nbsp;Raziyeh Ghorbani,&nbsp;Roya Fattahi","doi":"10.1155/dth/7050751","DOIUrl":"https://doi.org/10.1155/dth/7050751","url":null,"abstract":"<p>Skin regeneration is a complex and highly coordinated process involving multiple cell types, cytokines, growth factors, and extracellular matrix remodeling. This tightly regulated process allows efficient tissue repair through angiogenesis, reepithelialization, and controlled scar formation. Oxygen plays a crucial role in wound healing by participating in metabolic activities and energy production necessary for the healing process. It is important in all phases of healing, including acute, chronic, and surgical wounds, where it regulates cell proliferation, migration, survival, extracellular matrix synthesis, and host defense mechanisms. In this review, we discuss the role of oxygen tension in modulating different stages of wound healing and highlight its clinical implications for tissue repair strategies.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7050751","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Janus Kinase Inhibitors in the Treatment of Genodermatoses: A Systematic Review","authors":"Pin-Chun Chen,&nbsp;Chih-Chiang Chen,&nbsp;Sheng-Hsiang Ma,&nbsp;Tai-Li Chen","doi":"10.1155/dth/5123844","DOIUrl":"https://doi.org/10.1155/dth/5123844","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Genodermatoses are rare inherited skin disorders with limited treatment options. Emerging evidence suggests Janus kinase (JAK) inhibitors may offer therapeutic benefits by modulating underlying immune and inflammatory pathways. This study aims to systematically review the efficacy and safety of JAK inhibitors in treating genodermatoses, including epidermolysis bullosa (EB), Netherton syndrome, and Hailey-Hailey disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive literature search identified case reports and series evaluating JAK inhibitor therapy in genodermatoses. Quality assessment was performed using the Joanna Briggs Institute Critical Appraisal Tools for Case Reports, demonstrating high methodological quality across included studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Twenty studies involving patients with EB subtypes (especially dystrophic EB), Netherton syndrome, and other inherited dermatoses reported clinical improvement following treatment with JAK inhibitors such as tofacitinib, baricitinib, and upadacitinib. Outcomes included reduction in pruritus, skin inflammation, and lesion severity, with notable improvements in quality-of-life measures. Treatment regimens varied (e.g., tofacitinib 5 mg twice daily, baricitinib 2 mg once daily, and upadacitinib 15 mg once daily) with follow-up ranging from weeks to months. Laboratory monitoring showed stable profiles without significant adverse events. Reports of adverse events were rare or absent across studies, indicating favorable safety profiles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>JAK inhibitors represent a promising therapeutic avenue for genodermatoses characterized by immune dysregulation and chronic inflammation. While preliminary data are encouraging, further controlled studies are warranted to establish long-term efficacy and safety. These findings support expanded clinical investigation of JAK inhibition in managing inherited skin disorders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5123844","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tildrakizumab for Systemic-Treatment-Eligible Plaque Psoriasis: A Retrospective Real-World Study in Chinese Patients","authors":"Meijiao Xu,&nbsp;Jingwen Zhang,&nbsp;Xiaojian Chen,&nbsp;Ruochen Zhang,&nbsp;He Huang,&nbsp;Bo Zhang,&nbsp;Shengru Zhou,&nbsp;Min Chen,&nbsp;Qianqian Zhou,&nbsp;Huizi Xiong,&nbsp;Min Li,&nbsp;Xuejun Zhang","doi":"10.1155/dth/9941211","DOIUrl":"https://doi.org/10.1155/dth/9941211","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Real-world data on tildrakizumab in Chinese patients with plaque psoriasis remain limited, particularly in patients treated in routine practice based on systemic treatment eligibility rather than trial-style severity thresholds.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To assess the effectiveness and safety of tildrakizumab in Chinese patients with plaque psoriasis over a 28-week follow-up period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adults with plaque psoriasis eligible for systemic therapy were enrolled in this multicenter, retrospective, observational study. Psoriasis area and severity index (PASI), body surface area (BSA), and dermatology life quality index (DLQI) were evaluated at baseline, Week 16, and Week 28. Adverse events (AEs) were collected simultaneously.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 59 patients were included (72.9% male, median age 39.0 years), with baseline PASI, BSA, and DLQI of 6.0 ± 6.3, 8.3 ± 10.4%, and 8.2 ± 7.2, respectively. At Week 16, PASI 75, PASI 90, and PASI 100 responses were achieved in 64.3%, 42.9%, and 38.1% of evaluable patients, respectively; corresponding rates at Week 28 were 79.5%, 70.5%, and 54.5%. Absolute PASI targets (PASI ≤ 3 and PASI ≤ 1) were achieved by 90.5% and 66.7% at Week 16, and 97.7% and 81.8% at Week 28, respectively. Mean PASI, BSA, and DLQI all significantly improved from baseline at follow-up visits. At Week 28, 77.5% of patients achieved DLQI 0/1. In subgroup analyses, biologic-naïve patients showed higher response rates than biologic-experienced patients at Week 28, although baseline disease severity differed between groups. AEs occurred in 6.8% of patients and were mild. No patients with latent <i>tuberculosis</i> encountered reactivation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this real-world study, tildrakizumab demonstrated significant effectiveness in Chinese patients with plaque psoriasis eligible for systemic therapy. No new safety signals were observed within the 28-week follow-up period.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9941211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intradermal Recombinant Humanized Collagen Type III for Melasma: Split-Face Randomized Comparison With Tranexamic Acid","authors":"Wenjie Li,&nbsp;Juan Li,&nbsp;Huiyun Fan,&nbsp;Fan Cui,&nbsp;Zhen Rang","doi":"10.1155/dth/2727867","DOIUrl":"https://doi.org/10.1155/dth/2727867","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Given limitations for current treatments of melasma, new safe and effective methods are being explored.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to compare the efficacy and safety of intradermal recombinant humanized type III collagen (rhCol III) with intradermal tranexamic acid (TXA) for the treatment of melasma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This randomized split-face controlled study enrolled 20 female patients with bilateral melasma. In each patient, one side of the face received monthly intradermal rhCol III (4 mg/mL) injection, while the contralateral side received intradermal TXA (50 mg/mL) injection, for a total of five treatment sessions. Treatment efficacy was assessed at baseline and 1 month after the final treatment using the VISIA skin imaging analysis system and dermoscopy. The Hemi-modified Melasma Area and Severity Index (Hemi-mMASI) was continuously evaluated through the 4-month posttreatment follow-up. Patient satisfaction and pain intensity, assessed using the visual analog scale (VAS), were also recorded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both intradermal rhCol III and TXA injections significantly improved Hemi-mMASI scores (<i>p</i> &lt; 0.001), with no significant difference in the degree of melasma improvement between the two treatments. Pain intensity was significantly higher during TXA injection than during rhCol III injection (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Intradermal rhCol III and TXA injections were both effective and well tolerated for melasma. Both treatments may serve as promising adjunctive options in combination treatment strategies for melasma. Compared with TXA, rhCol III showed comparable efficacy in improving melasma severity and was associated with less injection-related pain.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2727867","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Biologic Failure in Moderate-to-Severe Plaque Psoriasis: Retrospective Multivariable Analysis in China","authors":"Ying Zhou,&nbsp;Weiquan Chen,&nbsp;Litian Zhang,&nbsp;Kun Zhong","doi":"10.1155/dth/7576221","DOIUrl":"https://doi.org/10.1155/dth/7576221","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Secondary failure (SF) to biologic therapies (BTs), defined as the loss of efficacy after initial treatment success, poses a significant challenge to moderate-to-severe plaque psoriasis treatment. While SF predictors have been explored in Western populations, data remain scarce among Chinese patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To identify demographic, clinical, and treatment-related predictors of SF to BTs in Chinese patients with moderate-to-severe plaque psoriasis using real-world registry data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter retrospective cohort study used China Psoriasis Center Register data. Kaplan–Meier survival analysis and multivariate Cox regression were applied to assess predictors of SF.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 409 eligible patients (mean age: 46.2% and 69.4% male), 46 (11.2%) experienced SF during follow-up (median = 166 days, interquartile range 93–365 days). Most patients received anti–IL-17A therapy, particularly secukinumab. Multivariate analysis confirmed independent risks for advancing age (adjusted HR [aHR] = 1.02 per year, 95% CI: 1.00–1.05, <i>p</i> = 0.037) and lower DLQI (aHR = 0.95 per unit increase, 95% CI: 0.91–1.00, <i>p</i> = 0.046); first-time use remained protective (aHR = 0.48, 95% CI: 0.26–0.89, <i>p</i> = 0.021). Sex, smoking, and metabolic comorbidities showed no significant associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Advancing age, prior BT use, and lower baseline DLQI scores may independently predict SF. First-line BT initiation and baseline quality-of-life impairment may be associated with improved treatment durability. Vigilant monitoring in high-risk subgroups and baseline quality-of-life assessments are crucial.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7576221","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibroblast Biology in Skin Aging and Rejuvenation","authors":"Maurizio Cavallini","doi":"10.1155/dth/9742005","DOIUrl":"https://doi.org/10.1155/dth/9742005","url":null,"abstract":"<p>Fibroblasts are the principal mesenchymal cells of the dermis and comprise heterogeneous papillary, reticular, and dermo–hypodermal populations with distinct roles in extracellular matrix (ECM) production, tissue repair, and skin aging. Oxidative stress, ultraviolet exposure, and collagen fragmentation impair fibroblast–ECM interactions and mechanotransduction, contributing to reduced Type I and III collagen synthesis, increased matrix metalloproteinase activity, dermal thinning, laxity, and loss of elasticity. This narrative review summarizes current evidence on dermal fibroblast heterogeneity, senescence, mechanobiology, and their relevance to aesthetic and regenerative dermatology. Injectable biomaterials, energy-based devices, platelet-rich plasma, exosome-rich formulations, and stem cell–conditioned media may influence fibroblast activity through mechanical, thermal, or paracrine mechanisms. However, the level of evidence varies substantially across modalities, ranging from biopsy-controlled human studies and randomized trials for selected interventions to predominantly preclinical or small exploratory studies for emerging approaches. Fibroblast compartmentalization provides a rationale for depth-oriented treatment strategies. Superficial interventions, such as non–cross-linked hyaluronic acid and fractional lasers, may preferentially affect the papillary dermis, whereas deeper modalities, including calcium hydroxylapatite, poly-L-lactic acid, radiofrequency, and focused ultrasound, may engage reticular and deeper dermal compartments. Emerging layered biostimulation protocols aim to combine modalities acting at different tissue depths, but this approach remains supported mainly by mechanistic reasoning and uncontrolled clinical experience rather than direct comparative trials. Future directions include senescence-targeted therapies, metabolic and mitochondrial support strategies, and biomaterials designed to combine structural support with controlled biochemical signaling. These approaches remain largely preclinical or early stage in aesthetic dermatology. Overall, fibroblast biology provides a mechanistic framework for interpreting current and emerging rejuvenation strategies, but standardized clinical protocols will require stronger human evidence, harmonized outcome measures, and long-term safety data.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9742005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese Medicine Monomers for Psoriasis: Mechanistic Insights, Evidence, and Translational Perspectives","authors":"Wenfei Luo,&nbsp;Huijuan Shi","doi":"10.1155/dth/3731758","DOIUrl":"https://doi.org/10.1155/dth/3731758","url":null,"abstract":"<p>Psoriasis is a chronic inflammatory skin disease characterized by immune dysregulation and abnormal keratinocyte proliferation. Traditional Chinese medicine (TCM) monomers, including quercetin, rutin, paeonol, resveratrol, oxymatrine, and ginsenosides, have attracted increasing attention as potential therapeutic candidates. This review summarizes their antipsoriatic effects and molecular mechanisms, focusing on anti-inflammatory, antioxidant, immunomodulatory, and antiproliferative activities involving key pathways such as IL-23/IL-17, NF-κB, JAK/STAT3, PI3K/AKT, and Nrf2 signaling. Although preclinical studies have shown promising effects in alleviating psoriasis-like inflammation and modulating pathogenic pathways, clinical evidence remains limited. This review further discusses the translational potential of TCM monomers from the perspectives of advanced topical and transdermal delivery systems, combination therapy, biomarker-guided treatment, and quality-controlled clinical development. Future studies should prioritize standardized formulations, pharmacokinetic optimization, long-term safety evaluation, and well-designed randomized controlled trials to determine their potential value as adjunctive therapeutic candidates for psoriasis.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/3731758","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-Reported Outcomes and Acceptability of a Microbiome-Targeting Dermocosmetic Cream Used as Adjunct to Acne Treatment in Japanese Women: A Real-World Pilot Study","authors":"Atsuyuki Igarashi,&nbsp;Masatoshi Abe,&nbsp;Yurie Gunji,&nbsp;Osamu Nemoto,&nbsp;Kuniko Kawamura,&nbsp;Delphine Kerob,&nbsp;Mayumi Yokozeki,&nbsp;Atsushi Saito,&nbsp;Akira Ookawara","doi":"10.1155/dth/1437881","DOIUrl":"https://doi.org/10.1155/dth/1437881","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acne is a common skin disease in Japanese women that is associated with a marked negative impact on quality of life. Increasing evidence from acne studies indicates that good skincare with over-the-counter (OTC) products with both cosmetic and therapeutic actions (dermocosmetics) may result in superior outcomes compared to medical therapy alone.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Real-world, pilot observational study evaluating the adjunctive twice-daily use of a dermocosmetic cream (niacinamide, panthenol, and pre- and postbiotic complex) in adult Japanese women receiving prescription acne treatment. Patient-reported outcomes (PROs), acceptability, and safety were assessed at baseline, Week 2, and Week 4.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 40 women participated with a mean age of 24.4 years. All patients used topical anti-acne treatment with 29 using topical antibiotics, 13 using benzoyl peroxide, 8 using topical retinoids, and 9 using combination drugs. There was a significant reduction in the number of noninflammatory acne lesions, and patients reported high satisfaction. In addition, the mean Cardiff Acne Disability Index total score was improved by Week 4. The dermocosmetic cream demonstrated good safety, with just one patient reporting itch as an adverse event that did not require study discontinuation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this real-world pilot study, adjunctive use of a dermocosmetic cream was well tolerated and associated with improvements in PROs and quality of life. These preliminary findings support further evaluation in controlled studies. The absence of a control group, the heterogeneity of concomitant prescription treatments, and the short study duration should be considered when interpreting these results.</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1437881","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultraviolet-Induced Fluorescence Dermatoscopy in the Management of Non-Neoplastic Dermatoses—A Narrative Review","authors":"Paweł Pietkiewicz,&nbsp;Natalia Salwowska,&nbsp;Anna Słomiak-Wąsik,&nbsp;Yasmeen Jabeen Bhat,&nbsp;Anna Waśkiel-Burnat,&nbsp;Cristian Navarrete-Dechent,&nbsp;Enzo Errichetti","doi":"10.1155/dth/1168293","DOIUrl":"https://doi.org/10.1155/dth/1168293","url":null,"abstract":"<p>Ultraviolet-induced fluorescence dermatoscopy (UVFD) is a novel, promising dermatoscopic modality that uses excitation–emission phenomena to visualize endogenous and exogenous fluorophores. By highlighting both visible-light emission signals and absorption patterns, it provides valuable diagnostic data that complement conventional dermatoscopy. Although its potential for diagnosing and monitoring various dermatoses has been increasingly recognized in recent years, the technique’s role in guiding management decisions has not been comprehensively reviewed. In this narrative review, we integrate current literature with the authors’ clinical experience to demonstrate how UVFD can guide management across inflammatory, infectious, pigmentary, and scalp disorders. Specifically, we focus on how the presence or absence of particular fluorescence patterns—originating from organism-derived fluorophores, inflammatory metabolites, and treatment-related changes—may reflect disease activity, predict prognosis, confirm therapeutic response, or serve as a test of cure.</p>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1168293","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Solid Lipid Nanoparticle–Loaded Acanthus ebracteatus Vahl. Extract for Androgenic Alopecia Treatment: A Randomized, Controlled, Open-Label, Four-Arm Parallel-Group Clinical Study","authors":"Vanuchawan Wisuitiprot,&nbsp;Panlop Chakkavittumrong,&nbsp;Kornkanok Ingkaninan,&nbsp;Wudtichai Wisuitiprot,&nbsp;Neti Waranuch","doi":"10.1155/dth/5897441","DOIUrl":"https://doi.org/10.1155/dth/5897441","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Androgenic alopecia (AGA) is a common type of hair loss, caused by the metabolism of testosterone into dihydrotestosterone and hair follicular microinflammation. <i>Acanthus ebracteatus</i> Vahl. (AE) extract has been reported as a promising anti-hair loss agent. This article aims to clinically investigate the efficacy and safety of hair serum containing solid lipid nanoparticle–loaded AE in AGA volunteers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The current study aimed to evaluate the efficacy of a hair serum containing SLN-AE extract (SLN-AE serum) and 5% minoxidil in the treatment of AGA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Seventy-two men with AGA were randomized to receive SLN-AE serum, 5% minoxidil, a combination treatment (SLN-AE serum + 5% minoxidil), or placebo, twice daily for 6 months. Clinical outcomes were assessed through hair count, global photographic review, hair shedding, and participant satisfaction with hair regrowth.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The results revealed that SLN-AE serum significantly improved hair regrowth, as evidenced by an increase in total hair count and the density of anagen hairs, as well as a significant decrease in the density of telogen hairs. The combination treatment also demonstrated effectiveness in increasing hair count at the earliest time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The clinical outcomes indicate that AE extract is a promising candidate for AGA treatment due to its safety and effectiveness.</p>\u0000 \u0000 <p><b>Trial Registration:</b> Thai Clinical Trial Registry: TCTR20240318001</p>\u0000 </section>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2026 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/5897441","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}